PRINCETON, N.J., Oct. 23 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the BIO Investor Forum in San Francisco. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentation will be held on Wednesday, October 29, 2008 at 1:45 PM PDT in the Marina Room of the Palace Hotel.
The company is also pleased to announce that Dr. Arthur Louie, chief medical officer, has been invited to participate in a therapeutic workshop titled, "Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon." The workshop will be held on Thursday, October 30, 2008 at 9:30 AM PDT in the Twin Peak South Room of the Palace Hotel.
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and
Vancouver, BC, is a privately held pharmaceutical company developing new
and more effective therapies to treat cancer. CombiPlex(R), the company's
drug ratio technology platform, represents a revolutionary new approach to
the development of combination therapies based on identifying a fixed,
synergistic ratio of the drugs pre-clinically, incorporating that ratio in
a drug delivery vehicle and maintaining the ratio in patients. The company
pipeline includes: CPX-1 (a liposomal formulation of
irinotecan:floxuridine), currently in a Phase 2 trial in patients with
colorectal cancer; CPX-351 (a liposomal formulation of
cytarabine:daunorubicin), currently in a Phase 1 trial in patients with
advanced leukemia; CPX-571 (a liposomal formulation of
irinotecan:cisplatin), a preclinical stage compound; and multiple research
programs. Based on the applications of CombiPlex, Celator is positioned to
advance a broad pipeline of combination therapies involving both previously
approved and novel drug agents. For more information, please visit the
company's website at http:/
|SOURCE Celator Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved